06.06.2025 • NewsDowMergers & Acquisitions (M&A)

Dow Sells its 50% Ownership in DowAksa

Dow announced that it has signed a sale and purchase agreement to sell its 50% interest in DowAksa to Aksa Akrilik Kimya Sanayii A.Ş., a company of Akkök Holding.

Dow logo outside a building
© JHVEPhoto - stock.adobe.com

Aksa Aksa Akrilik Kimya Sanayii A.Ş., the other 50% joint venture partner, has agreed to acquire Dow's 50% interest. Dow's proceeds from the sale are expected to be $125 million, which reflects, after accounting for debt, an enterprise value of approximately 10x the estimated 2025 operating EBITDA.

Dow's decision to exit the joint venture, which was formed in 2012, is consistent with Dow's best-owner mindset strategy of focusing on its core, high-value downstream businesses. The proceeds from the transaction will be used to support the Company's balanced capital allocation approach.

The sale is expected to close in the third quarter of 2025, subject to customary regulatory approvals and other closing conditions.

BNP Paribas acted as exclusive financial advisor to Dow on this transaction.

Company

DOW Chemical Company

Fox Court, 14 Gray's Inn
London WC11X 8WS
UK

Company contact







Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.